In a strategic shift, biotechnology company LungLife announced its decision to delist its shares from the Alternative Investment Market (AIM) of the London Stock Exchange. This decision follows a deal to sell its intellectual property assets, a move that marks a significant change in the company’s market presence and future operational strategy. The company has called a shareholder meeting to secure approval for this action.
For more detailed information on this development, you can explore the report on Law360.